TGFB1 and neoplasm: These strategies (reviewed in Bonaventura et al. [20]) include epigenetic drugs like demethylating agents to reverse silencing of TH1-type chemokines, tumor vaccines and oncolytic viruses to improve the immunogenicity of tumors, antiangiogenic and anti-TGF-β therapies to reverse exclusion of immune cells from tumor bed and immune cytokines to promote lymphocytes expansion at the tumor site.